[
  {
    "ts": null,
    "headline": "Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms",
    "summary": "US equity indexes rose at the close on Tuesday as gains in healthcare stocks helped offset declines",
    "url": "https://finnhub.io/api/news?id=99313131e7cf3d82c030e71c9dcfc47a822c2fd036838e289d7fe78aa2289d52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759266345,
      "headline": "Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms",
      "id": 136944051,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "US equity indexes rose at the close on Tuesday as gains in healthcare stocks helped offset declines",
      "url": "https://finnhub.io/api/news?id=99313131e7cf3d82c030e71c9dcfc47a822c2fd036838e289d7fe78aa2289d52"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
    "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
    "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759265220,
      "headline": "Pfizer Stock Soars on Trump’s New Drug Pricing Plan. Here’s Why.",
      "id": 136944001,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
      "url": "https://finnhub.io/api/news?id=04fbe0d5e9ce27db4ee3192e9532cb87df0019d8869b7be49ff119c8cd315884"
    }
  },
  {
    "ts": null,
    "headline": "Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.",
    "url": "https://finnhub.io/api/news?id=2a303d0f544c09c5d433aaba8d910781d5c52bf5166ff6cd6199b95c16b00c71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759262740,
      "headline": "Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know",
      "id": 136944190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.",
      "url": "https://finnhub.io/api/news?id=2a303d0f544c09c5d433aaba8d910781d5c52bf5166ff6cd6199b95c16b00c71"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Securities Maintains a Sell Rating on Amgen (AMGN)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00. The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing […]",
    "url": "https://finnhub.io/api/news?id=892253d053049751d284fc82ebe97492a5b2e58cc36f12354286319d4307e4e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759258177,
      "headline": "Bank of America Securities Maintains a Sell Rating on Amgen (AMGN)",
      "id": 136944226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00. The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing […]",
      "url": "https://finnhub.io/api/news?id=892253d053049751d284fc82ebe97492a5b2e58cc36f12354286319d4307e4e6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Trump Deal Eases Drug Pricing, Tariff Pressure. Drug Stocks Are Up.",
    "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
    "url": "https://finnhub.io/api/news?id=1666c915b2da3b20d51b77899d92ea8a7a5bb5de7d9c157cdd6fe2adbce9e405",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759251960,
      "headline": "Pfizer’s Trump Deal Eases Drug Pricing, Tariff Pressure. Drug Stocks Are Up.",
      "id": 136937733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The president announced a federal government website that allows Pfizer to sell medicines at low prices to cash-paying consumers.",
      "url": "https://finnhub.io/api/news?id=1666c915b2da3b20d51b77899d92ea8a7a5bb5de7d9c157cdd6fe2adbce9e405"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Growth Catalysts Incoming",
    "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
    "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759249535,
      "headline": "Regeneron: Growth Catalysts Incoming",
      "id": 136939389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962383/image_1386962383.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.",
      "url": "https://finnhub.io/api/news?id=bb66c6e3504758db315ceacc9eb99a4641b7f297c884b7e7544ade750efc5d34"
    }
  },
  {
    "ts": null,
    "headline": "Amgen to expand US drug production with $650M investment",
    "summary": "The California-based firm said it will create 750 jobs and support advanced technology upgrades throughout the Juncos, Puerto Rico, facility.",
    "url": "https://finnhub.io/api/news?id=0a76c3f2930d0e569796e1dfc4ef4657aaa254a301fe63488746b574496f763a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759236360,
      "headline": "Amgen to expand US drug production with $650M investment",
      "id": 136937734,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The California-based firm said it will create 750 jobs and support advanced technology upgrades throughout the Juncos, Puerto Rico, facility.",
      "url": "https://finnhub.io/api/news?id=0a76c3f2930d0e569796e1dfc4ef4657aaa254a301fe63488746b574496f763a"
    }
  }
]